Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ, Poveda JL, Rivero A, Serra-Baldrich E, Silvestre JF, Armario-Hita JC, Calleja MÁ, Carrascosa JM, Flórez Á, Herranz P, Comellas M, Ortiz de Frutos FJ. Pereyra-Rodríguez JJ, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e59-e62. doi: 10.1111/jdv.19432. Epub 2023 Aug 23. J Eur Acad Dermatol Venereol. 2024. PMID: 37594914 No abstract available.
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: carrascosa jm. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, De la Cueva Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Peral F, Torrado R, Rivera R, Jiménez-Puya R, Mendiola MV, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):907-14. doi: 10.1111/jdv.12208. Epub 2013 Jul 15. J Eur Acad Dermatol Venereol. 2014. PMID: 23848131
Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations.
Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, Ferrándiz L, Sánchez-Carazo JL, Daudén E, López-Estebaranz JL, Vidal D, Herranz P, Jorquera E, Coto-Segura P, Ribera M. Carrascosa JM, et al. Actas Dermosifiliogr. 2016 Apr;107(3):194-206. doi: 10.1016/j.ad.2015.10.005. Epub 2015 Nov 21. Actas Dermosifiliogr. 2016. PMID: 26614486 Free article. Review. English, Spanish.
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group. Belinchón I, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6. J Eur Acad Dermatol Venereol. 2017. PMID: 28485816
Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.
de la Cueva Dobao P, Notario J, Ferrándiz C, López Estebaranz JL, Alarcón I, Sulleiro S, Borrás J, Daudén E, Carrascosa JM, Sánchez Carazo JL, Monte Boquet E, Puig L. de la Cueva Dobao P, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1214-1223. doi: 10.1111/jdv.15600. Epub 2019 Apr 29. J Eur Acad Dermatol Venereol. 2019. PMID: 31037770
The Use of Apremilast in Psoriasis: A Delphi Study.
Carrascosa JM, Belinchón I, Rivera R, Ara M, Bustinduy M, Herranz P. Carrascosa JM, et al. Actas Dermosifiliogr (Engl Ed). 2020 Mar;111(2):115-134. doi: 10.1016/j.ad.2019.07.005. Epub 2019 Dec 19. Actas Dermosifiliogr (Engl Ed). 2020. PMID: 31864537 Review. English, Spanish.
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C, Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Carrascosa JM. Del Alcázar E, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2821-2829. doi: 10.1111/jdv.16439. Epub 2020 Jun 17. J Eur Acad Dermatol Venereol. 2020. PMID: 32271966
340 results